Cellergy Pharma

Executive Summary

Cellergy Pharma is a San Diego-based biotechnology company pioneering the application of CAR T cell therapy beyond oncology into immune-mediated diseases. Founded in 2017, the company is developing a first-in-class CAR T immunotherapy designed to treat severe allergic diseases by targeting and eliminating IgE-producing cells at their source. By redirecting the power of CAR T cells to B cells that produce IgE, Cellergy aims to provide a durable, potentially curative treatment for patients with severe allergies who are unresponsive to existing therapies. The platform leverages established CAR T manufacturing and safety mechanisms while addressing a large unmet need in allergic disease, a market estimated to affect hundreds of millions globally. With no publicly disclosed financing rounds or clinical-stage data, Cellergy remains an early-stage, privately held entity focused on preclinical development and IND-enabling studies. The company's success hinges on demonstrating proof-of-concept in relevant animal models and advancing to first-in-human trials, which would validate the approach and attract strategic partnerships or funding.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Candidate30% success
• Q3 2026Preclinical Efficacy Data Presentation50% success
• TBDSeries A or Seed Funding Announcement40% success